This month’s issue focuses on treating acne and rosacea, two conditions that present regularly to dermatology offices across the country and that plague patients of all ages. Here’s a look at some of the content from this issue. In this month’s cover story, which begins on page 24, Managing Editor Ellen Meyer highlights recent research and trends in the Acne and Rosacea Review. If you missed the American Academy of Dermatology’s summer meeting in Boston last month or attended but didnt have a chance to view all the posters, this review includes a roundup of the acne posters presented as well as research briefs on new rosacea studies.
Beginning on page 28, Dr. Jennifer Linder shares her tips for positive treatment outcomes when treating acne in ethnic skin. Dr. Linder notes, “The variability in skin thickness, barrier function, sebaceous and eccrine gland activity, and the melanogenesis and inflammatory response can significantly affect treatment outcome.” In this article, you’ll read about the epidermal and dermal differences between ethnicities and find tips for effective ingredient choices for higher Fitzpatrick skin types. Next, Dr. James Del Rosso covers the role of fixed-dose combination topical therapy in treating acne vulgaris in this month’s Pharmacotherapy Update, which starts on page 33. “Since no one agent addresses all four key aspects of acne pathophysiology, most patients should be treated with more than one agent to control their disease,” explains Dr. Del Rosso.
This article reviews the effective fixed-drug combinations currently available and the need to tailor treatment according to patient preference and tolerability. As compliance is always an issue, the best treatment choice is usually the one that will encourage compliance from a patient. Tetracyclines in Acne and Rosacea, which begins on page 38, offers a complete overview of the characteristics of tetracyclines and their effective role in treating these two conditions. The authors, Ali Alikhan, Laura Kurek, and Dr. Steven R. Feldman, review why tetracyclines have a place as first-line agents in inflammatory acne and may be effective monotherapeutic agents in rosacea. Finally, on page 48, Dr. Noah Scheinfeld discusses why dermatologists need to consider drug-induced acne or acneiform types of folliculitis in their diagnoses with a review of medications that commonly cause these types of reactions.
We hope you enjoy this issue and learn something new about treating these common conditions.
Sincerely, Stefanie Tuleya Executive Editor stuleya@hmpcommunications.com
This month’s issue focuses on treating acne and rosacea, two conditions that present regularly to dermatology offices across the country and that plague patients of all ages. Here’s a look at some of the content from this issue. In this month’s cover story, which begins on page 24, Managing Editor Ellen Meyer highlights recent research and trends in the Acne and Rosacea Review. If you missed the American Academy of Dermatology’s summer meeting in Boston last month or attended but didnt have a chance to view all the posters, this review includes a roundup of the acne posters presented as well as research briefs on new rosacea studies.
Beginning on page 28, Dr. Jennifer Linder shares her tips for positive treatment outcomes when treating acne in ethnic skin. Dr. Linder notes, “The variability in skin thickness, barrier function, sebaceous and eccrine gland activity, and the melanogenesis and inflammatory response can significantly affect treatment outcome.” In this article, you’ll read about the epidermal and dermal differences between ethnicities and find tips for effective ingredient choices for higher Fitzpatrick skin types. Next, Dr. James Del Rosso covers the role of fixed-dose combination topical therapy in treating acne vulgaris in this month’s Pharmacotherapy Update, which starts on page 33. “Since no one agent addresses all four key aspects of acne pathophysiology, most patients should be treated with more than one agent to control their disease,” explains Dr. Del Rosso.
This article reviews the effective fixed-drug combinations currently available and the need to tailor treatment according to patient preference and tolerability. As compliance is always an issue, the best treatment choice is usually the one that will encourage compliance from a patient. Tetracyclines in Acne and Rosacea, which begins on page 38, offers a complete overview of the characteristics of tetracyclines and their effective role in treating these two conditions. The authors, Ali Alikhan, Laura Kurek, and Dr. Steven R. Feldman, review why tetracyclines have a place as first-line agents in inflammatory acne and may be effective monotherapeutic agents in rosacea. Finally, on page 48, Dr. Noah Scheinfeld discusses why dermatologists need to consider drug-induced acne or acneiform types of folliculitis in their diagnoses with a review of medications that commonly cause these types of reactions.
We hope you enjoy this issue and learn something new about treating these common conditions.
Sincerely, Stefanie Tuleya Executive Editor stuleya@hmpcommunications.com
This month’s issue focuses on treating acne and rosacea, two conditions that present regularly to dermatology offices across the country and that plague patients of all ages. Here’s a look at some of the content from this issue. In this month’s cover story, which begins on page 24, Managing Editor Ellen Meyer highlights recent research and trends in the Acne and Rosacea Review. If you missed the American Academy of Dermatology’s summer meeting in Boston last month or attended but didnt have a chance to view all the posters, this review includes a roundup of the acne posters presented as well as research briefs on new rosacea studies.
Beginning on page 28, Dr. Jennifer Linder shares her tips for positive treatment outcomes when treating acne in ethnic skin. Dr. Linder notes, “The variability in skin thickness, barrier function, sebaceous and eccrine gland activity, and the melanogenesis and inflammatory response can significantly affect treatment outcome.” In this article, you’ll read about the epidermal and dermal differences between ethnicities and find tips for effective ingredient choices for higher Fitzpatrick skin types. Next, Dr. James Del Rosso covers the role of fixed-dose combination topical therapy in treating acne vulgaris in this month’s Pharmacotherapy Update, which starts on page 33. “Since no one agent addresses all four key aspects of acne pathophysiology, most patients should be treated with more than one agent to control their disease,” explains Dr. Del Rosso.
This article reviews the effective fixed-drug combinations currently available and the need to tailor treatment according to patient preference and tolerability. As compliance is always an issue, the best treatment choice is usually the one that will encourage compliance from a patient. Tetracyclines in Acne and Rosacea, which begins on page 38, offers a complete overview of the characteristics of tetracyclines and their effective role in treating these two conditions. The authors, Ali Alikhan, Laura Kurek, and Dr. Steven R. Feldman, review why tetracyclines have a place as first-line agents in inflammatory acne and may be effective monotherapeutic agents in rosacea. Finally, on page 48, Dr. Noah Scheinfeld discusses why dermatologists need to consider drug-induced acne or acneiform types of folliculitis in their diagnoses with a review of medications that commonly cause these types of reactions.
We hope you enjoy this issue and learn something new about treating these common conditions.
Sincerely, Stefanie Tuleya Executive Editor stuleya@hmpcommunications.com
